Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

BACKGROUND: At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into adulthood. The objectives of this analysis were to d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Arthritis Res Ther
Main Authors: Armaroli, Giulia, Klein, Ariane, Ganser, Gerd, Ruehlmann, Michael J., Dressler, Frank, Hospach, Anton, Minden, Kirsten, Trauzeddel, Ralf, Foeldvari, Ivan, Kuemmerle-Deschner, Jasmin, Weller-Heinemann, Frank, Urban, Andreas, Horneff, Gerd
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7597050/
https://ncbi.nlm.nih.gov/pubmed/33121528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02326-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares